Astaxanthin / ChemoSen Cancer Research Results

ASTX, Astaxanthin: Click to Expand ⟱
Features:

Astaxanthin — a lipophilic xanthophyll carotenoid antioxidant (often sourced from Haematococcus pluvialis microalgae and also present in salmon/crustaceans) used as a nutraceutical with prominent redox and inflammation-modulating biology. It is formally classified as a small-molecule dietary carotenoid (natural product / nutraceutical). Common abbreviations include ASTX and AXT. In oncology-context literature it is primarily discussed as a chemopreventive/cytoprotective redox modulator with context-dependent direct antitumor effects, and with theoretical concern for antagonizing ROS-mediated chemo/radiation mechanisms in some settings.
The European Commission considers natural astaxanthin as a food dye

Primary mechanisms (ranked):

  1. NRF2 pathway activation with downstream antioxidant/phase-II enzyme program (context-dependent; often cytoprotective)
  2. Suppression of inflammatory signaling including NF-κB axis with downstream COX-2/iNOS and cytokine modulation
  3. Growth/survival signaling modulation (context-dependent), commonly reported on PI3K–AKT, ERK/MAPK, STAT3
  4. Mitochondria-linked apoptosis induction and cell-cycle perturbation in select tumor models (dose/model-dependent)
  5. Anti-migration/anti-EMT phenotype (e.g., MMPs, cadherin switch; model-dependent)
  6. Ferroptosis/redox-lethal interactions reported in limited models (model-dependent)

Bioavailability / PK relevance: Poor aqueous solubility and variable oral absorption (fat/formulation-dependent). Plasma exposure is typically low with standard oral supplements; engineered formulations (micellar/nanoemulsion) can increase Cmax and shorten Tmax. Reported terminal half-life in healthy volunteers is on the order of ~1–2 days in at least one human PK study.

In-vitro vs systemic exposure relevance: Many mechanistic cancer studies use micromolar astaxanthin concentrations that can exceed typical human plasma levels after supplementation; therefore, mechanistic claims are frequently concentration- and formulation-limited for systemic antitumor translation.

Clinical evidence status: Predominantly preclinical (cell/animal) for direct anticancer claims. Human evidence is stronger for oxidative stress/inflammation biomarker modulation than for anticancer efficacy endpoints; not an approved anticancer drug. Practical oncology use is mainly adjunctive/chemopreventive framing, with caution discussed around concurrent ROS-dependent chemo/radiation.

Astaxanthin is a xanthophyll carotenoid with exceptionally strong antioxidant capacity. In cancer biology, it shows context-dependent effects—largely chemopreventive and cytoprotective, with limited evidence as a direct antineoplastic agent.
Astaxanthin significantly promotes the proliferation of Akkermansia, a microorganism with enhanced anti-tumor immune effects.
Anti-inflammatory signaling, Astaxanthin can inhibit: NF-κB, COX-2, iNOS
Astaxanthin commonly Activates NRF2: Upregulates antioxidant enzymes (GSH, SOD, CAT, GPX)
-Protective in normal tissues
-Potentially tumor-protective in established cancers

Often discouraged during active chemotherapy or radiation
It may:
-Protect tumor cells from ROS-mediated killing
-Reduce lipid peroxidation-based therapies
This concern is similar to:
-Vitamin E
-Trolox
-High-dose carotenoids

Astaxanthin is less likely to be pro-oxidant than lycopene or β-carotene.
Some reports indicate a pro-oxidant effect, but at concentrations that are not achievable for in vito.

Astaxanthin — mechanistic pathway map (cancer-context)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 NRF2 antioxidant response ↑ NRF2 (context-dependent) → ↓ ROS injury; may blunt ROS-lethal therapies ↑ NRF2 → ↑ GSH/SOD/CAT/GPx; cytoprotection R/G Redox buffering and stress tolerance Often positioned as protective; in established tumors this can be tumor-supportive depending on therapy and redox state.
2 NF-κB inflammatory signaling ↓ NF-κB → ↓ pro-survival inflammation (model-dependent) ↓ inflammatory cytokine signaling R/G Anti-inflammatory microenvironment shift Commonly linked to ↓ COX-2/iNOS and reduced inflammatory tone.
3 PI3K–AKT survival signaling ↓ PI3K/AKT (model-dependent) → ↑ apoptosis, ↓ proliferation ↔ / mild cytoprotective bias (context-dependent) R/G Survival pathway suppression in select tumors Directionality is model- and dose-dependent; some datasets show mixed AKT effects.
4 ERK/MAPK signaling ↓ ERK/MAPK (model-dependent) → ↓ proliferation/EMT ↔ / ↓ stress-activated signaling (context-dependent) R/G Anti-growth signaling modulation Often reported alongside PI3K/AKT changes; may converge on apoptosis/cell-cycle effects.
5 STAT3 axis ↓ STAT3 → ↓ proliferation, ↓ immune-evasion programs (model-dependent) ↔ G Reduced oncogenic transcription signaling Reported in prostate and other models; typically framed as anti-tumor signaling.
6 Mitochondria-mediated apoptosis ↑ intrinsic apoptosis (BAX↑, Bcl-2↓, caspases↑; model-dependent) ↓ stress-induced apoptosis (cytoprotection) R Cell death modulation Key “anti-tumor” readout in many studies; may require higher concentrations than typical systemic exposure.
7 Cell cycle control ↑ p21/p27 and/or arrest signatures (model-dependent) ↔ G Proliferation braking Often co-occurs with apoptosis; direction varies with cell line and dosing.
8 EMT and matrix remodeling ↓ EMT; ↓ MMPs; ↑ E-cadherin (model-dependent) ↔ G Anti-migration / anti-metastatic phenotype Reported via miRNA and cadherin/MMP changes in some colon/breast models.
9 Angiogenesis signaling ↓ VEGF/EGFR signaling (limited, model-dependent) ↔ G Reduced pro-angiogenic drive Less consistently central than NRF2/NF-κB/PI3K–AKT in the literature.
10 Ferroptosis and lipid peroxidation balance ↔ / ↑ ferroptosis (limited models) but also ↓ lipid peroxidation (context-dependent) ↓ lipid peroxidation injury R Redox-lethal interaction or protection (context-dependent) Net effect depends strongly on baseline oxidative state and whether therapy relies on lipid peroxidation.
11 Clinical Translation Constraint Low/variable oral exposure; many in-vitro effects are high-concentration. Antioxidant/NRF2 biology raises a plausible antagonism risk for ROS-dependent chemo/radiation (context-dependent). Formulation and dosing strategy strongly influence exposure. — Translational ceiling Best-supported human domain is oxidative stress/inflammation biomarkers rather than anticancer efficacy endpoints.

TSF legend: P: 0–30 min    R: 30 min–3 hr    G: >3 hr
ChemoSen, chemo-sensitization: Click to Expand ⟱
Source:
Type:
The effectiveness of chemotherapy by increasing cancer cell sensitivity to the drugs used to treat them, which is known as “chemo-sensitization”.

Chemo-Sensitizers:
-Curcumin
-Resveratrol
-EGCG
-Quercetin
-Genistein
-Berberine
-Piperine: alkaloid from black pepper
-Ginsenosides: active components of ginseng
-Silymarin
-Allicin
-Lycopene
-Ellagic acid
-caffeic acid phenethyl ester
-flavopiridol
-oleandrin
-ursolic acid
-butein
-betulinic acid
Scientific Papers found: Click to Expand⟱
5424- ASTX,    Astaxanthin exerts an adjunctive anti-cancer effect through the modulation of gut microbiota and mucosal immunity
- in-vivo, Nor, NA
*GutMicro↑, AntiCan↑, eff↑, AntiTum↑, ChemoSen↑,
4816- ASTX,    Potent carotenoid astaxanthin expands the anti-cancer activity of cisplatin in human prostate cancer cells
- in-vitro, Pca, NA
*antiOx↑, *Inflam↓, ChemoSen↑, E-cadherin↑, N-cadherin↓, VEGF↓, cMyc↓, PSA↓, cl‑Casp3↑, PARP1↑,
4810- ASTX,    Effects of Astaxanthin on the Proliferation and Migration of Breast Cancer Cells In Vitro
- in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
TumCP↓, TumCMig↓, selectivity↑, *BDNF↑, *ROS↓, *TNF-α↓, *IL6↓, *IFN-γ↓, *NF-kB↓, BAX⇅, Bcl-2↓, *antiOx↑, radioP↑, ChemoSen↑,
4807- ASTX,    An overview of the anticancer activity of astaxanthin and the associated cellular and molecular mechanisms
- Review, Var, NA
*antiOx↑, *neuroP↑, AntiCan↑, TumCG↓, TumCD↑, TumCMig↓, ChemoSen↑, chemoP↑, *BioAv↓, TumCP↓, TumCCA↑, Apoptosis↑, BioAv↑,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   BAX⇅, 1,   Bcl-2↓, 1,   cl‑Casp3↑, 1,   TumCD↑, 1,  

DNA Damage & Repair ⓘ

PARP1↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Migration ⓘ

E-cadherin↑, 1,   N-cadherin↓, 1,   TumCMig↓, 2,   TumCP↓, 2,  

Angiogenesis & Vasculature ⓘ

VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

PSA↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   ChemoSen↑, 4,   eff↑, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   AntiTum↑, 1,   chemoP↑, 1,   radioP↑, 1,  
Total Targets: 24

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 3,   ROS↓, 1,  

Immune & Inflammatory Signaling ⓘ

IFN-γ↓, 1,   IL6↓, 1,   Inflam↓, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,  

Clinical Biomarkers ⓘ

GutMicro↑, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

neuroP↑, 1,  
Total Targets: 12

Scientific Paper Hit Count for: ChemoSen, chemo-sensitization
4 Astaxanthin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:382  Target#:1106  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page